Editorial expression of concern: miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer

Correction:Mol Cancer 13, 71 (2014)

https://doi.org/10.1186/1476-4598-13-71

Published: 24 March 2014

After the publication of this article, the publisher was alerted to an apparent panel duplication and frameshift in Fig. 4B migration (ii) SKBR3-LR NC mimic and 4 C invasion (ii) SKBR3-LR NC mimic. Because the issue was detected ten years after publication, the original images for the study are no longer available. The panel has not been replaced. Readers are urged to take caution when interpreting the content and conclusions of this article.

Authors and Affiliations

1. School of Pharmacy and Pharmaceutical Sciences & Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland

   Claire Corcoran, Sweta Rani, Susan Breslin, Martina Gogarty & Lorraine O’Driscoll

2. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

   Irene M Ghobrial

3. Department of Oncology, St. Vincent’s University Hospital, Dublin 4, Ireland

   John Crown

Authors

1. Claire CorcoranView author publications

   You can also search for this author in PubMed Google Scholar

2. Sweta RaniView author publications

   You can also search for this author in PubMed Google Scholar

3. Susan BreslinView author publications

   You can also search for this author in PubMed Google Scholar

4. Martina GogartyView author publications

   You can also search for this author in PubMed Google Scholar

5. Irene M GhobrialView author publications

   You can also search for this author in PubMed Google Scholar

6. John CrownView author publications

   You can also search for this author in PubMed Google Scholar

7. Lorraine O’DriscollView author publications

   You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lorraine O’Driscoll.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at https://doi.org/10.1186/1476-4598-13-71.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions

Cite this article

Corcoran, C., Rani, S., Breslin, S. et al. Editorial expression of concern: miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer. Mol Cancer 23, 219 (2024). https://doi.org/10.1186/s12943-024-02139-z

Download citation

• Published: 01 October 2024

• DOI: https://doi.org/10.1186/s12943-024-02139-z

Share this article

Anyone you share the following link with will be able to read this content:

Get shareable link

Sorry, a shareable link is not currently available for this article.

Copy to clipboard

Provided by the Springer Nature SharedIt content-sharing initiative